Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several statements align with the provided label excerpts on mechanism of action and immunizations (avoid live vaccines; consider completing immunizations before starting; counsel patients about live vaccines during treatment). However, multiple claims about vaccine-response effects (e.g., “generally expected to be less impaired”) and general allowances for inactivated/live vaccines, as well as broad statements that patients can “often still mount an immune response,” are not supported by the provided prescribing information excerpts and are therefore treated as unsupported.
Category Scores
Accurate Statements
Cosentyx (secukinumab) blocks interleukin-17A (IL-17A).
12.1 Mechanism of Action: selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines.
5.7 Immunizations: Prior to initiating therapy... consider completion of all age-appropriate immunizations...
Vaccine with live vaccines is not recommended during COSENTYX treatment.
5.7 Immunizations: COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX. Also repeated in 17 Patient Counseling Information under Immunization.
Patients should inform the healthcare practitioner that they are taking COSENTYX prior to a potential vaccination.
17 Patient Counseling Information (Immunization): Instruct patients to inform the healthcare practitioner that they are taking COSENTYX prior to a potential vaccination.
Clinicians should avoid live vaccines during COSENTYX treatment.
5.7 Immunizations: Avoid use of live vaccines in patients treated with COSENTYX.
Unsupported Statements
Because Cosentyx targets an inflammatory immune pathway rather than broadly suppressing antibody production, vaccine responses are generally expected to be less impaired than with some other immunosuppressive drugs.
The provided label excerpts do not state that vaccine responses are generally less impaired or compare to other immunosuppressive drugs.
Inactivated (non-live) vaccines are often preferred when vaccination is needed for many biologic immune-modulating therapies.
The provided label excerpts only explicitly address live vaccines; they do not state preferences for inactivated vaccines or generalize to “many biologic immune-modulating therapies.”
Live (attenuated) vaccines are often avoided due to safety concerns for many biologic immune-modulating therapies.
While live vaccines are to be avoided during COSENTYX treatment, the excerpt does not support the broader claim that this is due to “safety concerns for many” therapies.
Patients treated with immune-modulating biologics can often still mount an immune response to vaccines.
The provided label excerpts do not discuss whether patients can mount immune responses to vaccines while on COSENTYX.
Vaccine immune responses may vary based on vaccine type (inactivated vs live), baseline immune status and underlying disease, and timing of vaccination relative to dosing.
No such statements about variability factors are present in the provided excerpts.
Many vaccination strategies for immunomodulating drugs aim to vaccinate before starting treatment when feasible because immune responses may be more robust when the drug is not suppressing the target pathway.
The label supports considering completion of immunizations before initiating therapy, but does not state that immune responses may be more robust for that reason.
Clinicians may vaccinate during therapy if protection is needed urgently and the vaccine is appropriate.
The label excerpt provides instructions to avoid live vaccines during treatment and to inform healthcare practitioners about COSENTYX prior to potential vaccination, but does not support a general allowance to vaccinate during therapy for urgent protection.
Guidance typically aligns with general biologic principles in which inactivated vaccines are typically allowed and live vaccines are usually avoided.
The provided label excerpts do not state that inactivated vaccines are typically allowed, nor do they present “general biologic principles.”
Contradictions
Important Omissions
No label-cited statement specifying that live vaccines are contraindicated/avoided because COSENTYX may alter immune response to live vaccines is largely covered, but the provided response includes additional broad generalizations not supported; the only omission relevant to matching is that the response did not explicitly include the label wording that COSENTYX may alter immune response to live vaccines (beyond 'avoid live vaccines').
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported generalizations about vaccine response impairment and broad vaccine strategy (inactivated vaccines allowed/preferred; vaccinating during therapy when urgent) could mislead vaccination planning if taken as authoritative label guidance. The label excerpts specifically emphasize avoiding live vaccines during COSENTYX treatment and considering completion of age-appropriate immunizations prior to initiation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several broad vaccination-related claims (inactivated vaccine preference/allowance, vaccine response impairment magnitude, ability to mount responses, and permissibility of vaccinating during therapy) are not supported by the provided label excerpts.
Suggested Improvement
Limit vaccination statements to label-supported points: consider completing age-appropriate immunizations before starting COSENTYX; COSENTYX may alter immune response to live vaccines; avoid live vaccines during treatment; advise patients to inform healthcare practitioners about COSENTYX prior to potential vaccination. Remove or qualify unsupported generalizations about inactivated vaccines and relative vaccine-response impairment.